Hepatic Differentiation of Human Embryonic and Induced Pluripotent Stem Cells for Regenerative Medicine by Toshio Miki
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
16 
Hepatic Differentiation of Human Embryonic 
and Induced Pluripotent Stem Cells for 
Regenerative Medicine  
Toshio Miki 
Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC 
Department of Biochemistry and Molecular Biology, Keck School of Medicine 
University of Southern California, Los Angeles 
USA  
1. Introduction 
A hepatocyte is one of the most desired cells for regenerative medicine as well as for 
pharmaco-toxicological testing. Hepatocytes, the parenchymal cells of the liver, possess a 
wide range of functions, including protein synthesis/storage, detoxification, transformation 
of carbohydrates, synthesis of cholesterol, bile salts and phospholipids, as well as the 
excretion of exogenous and endogenous substances (Blouin et al 1977).  
The various functions of the liver are essential for the maintenance of the human body and 
liver failure is often only treatable by organ liver transplantation (OLT). The shortage of 
donated organs, however, limits this treatment option available to patients. Since the Model 
for End-Stage Liver Disease and Pediatric End-Stage Liver Disease (MELD/PELD) liver 
allocation system was introduced in February 2002, the usage of borderline-quality donated 
livers for OLT has increased (Freeman et al 2002). As a result, the number of patients on 
waiting lists for OLT has stabilized; however, more than 15,000 patients await OLT annually 
in the United of States alone (Thuluvath et al 2010).  
Hepatocyte transplantation (HT), a cell-replacement therapy for liver disease, could decrease 
the number of the patients on the waiting list. HT is particularly useful for metabolic liver 
diseases that do not require whole organ replacement but rather a partial restoration of specific 
liver metabolic functions (Fox et al 1998, Strom et al 1997). The feasibility and the therapeutic 
efficacy of HT have been demonstrated in several clinical trials (Strom et al 2006). However, 
the limited availability of human hepatocytes due to organ shortage prohibits the provision of 
this promising therapy to patients as a standard option. Human hepatocytes can be isolated 
from cadaveric livers that are donated but not suitable for OLT (Strom et al 1982). The number 
of unused donated livers has decreased since the MELD liver allocation system was initiated. 
This dilemma has led to an urgent demand for developing stem cell-derived functional human 
hepatocytes as an alternative. Stem cell-derived hepatocytes could also be utilized in artificial 
liver bio-devices for patients with acute liver failure who may not need the OLT (Gerlach et al 
2010, Gerlach et al 2008, Soto-Gutierrez et al 2006a). An unlimited supply of stem cell-derived 
hepatocytes could facilitate the development of these cell-based therapies for treatment of life-
threatening liver diseases. 
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Moreover, these stem cell-derived hepatocytes could be utilized not only for therapeutic 
applications but also for pharmaco-toxicological testing (Davila et al 2004). It is anticipated 
that stem cell-derived hepatocytes will be important as in vitro tools for testing drug safety, 
thereby significantly facilitating drug development. Toxicity assessment for drug 
development could be conducted with phenotypically and genotypically standardized 
human hepatocytes. In this regard, genetically homogeneous stem cell-derived hepatocytes 
would be superior to primary human hepatocytes. Human stem cell-derived hepatocytes 
would be particularly useful for conducting some infectious disease research as well. As a 
case in point, hepatocytes derived from animals have been demonstrated to not be useful for 
the study of human hepatitis virus biology such as HCV (Cai et al 2007). 
A number of different stem/progenitor cells have been proposed as an alternative cell 
source for generation of functional hepatocytes – these include fetal hepatocytes (Suzuki et 
al 2000), adult hepatic progenitor/stem (epithelial) cells (Alison & Sarraf 1998), bone-
marrow derived-stem cells (Gilchrist & Plevris 2010), and adipose-derived stem cells 
(Schaffler & Buchler 2007). Although the biological potential of fetal hepatocytes and adult 
hepatic progenitor cells is promising, ethical issues and limited availability hampers 
development for use in the clinic. Relatively small numbers of stem/progenitor cells would 
be insufficient for use to generate stem cell-derived hepatocytes in the clinic, particularly for 
HT, as HT recipients require transplantations of more than a billion cells at a time (Fox et al 
1998). Some reports claimed that there was hepatic differentiation of mesenchymal stem 
cells from adipose tissue or bone marrow. However, the differentiation to functional 
hepatocytes, remains controversial (Goodell 2003, Wagers & Weissman 2004). Further 
research efforts are required to gain consensus for utilizing these adult stem cell-derived 
hepatocytes in the clinic.  
To date, pluripotent stem cells are the most realistic candidate for the generation of stem cell-
derived hepatocytes. Pluripotent stem cells possess nearly unlimited self-renewal capability in 
vitro and are able to differentiate into all three germ layers. Human embryonic stem cells 
(hESCs) are derived from blastocysts (Thomson et al 1998), and several protocols have been 
published for the differentiation of hESCs to functional hepatocytes. Additionally, recent 
breakthroughs in the field of induced pluripotent stem (iPS) cell technology (Takahashi & 
Yamanaka 2006) have provided yet another promising source to generate stem cell-derived 
hepatocytes. The human iPS cells may overcome the ethical concerns of utilizing blastocyst-
derived pluripotent stem cell and may provide patient specific immunotype cells so as to 
avoid the lifelong use of immunosuppressants (Takahashi et al 2007). Disease-specific iPS cells, 
derived from patients who suffer from various congenital liver diseases, such as alpha1-
antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease, are 
anticipated to become important tools for studying the mechanisms underlying the 
pathogenesis of these diseases and investigations of new treatments (Ghodsizadeh et al 2010). 
Moreover, human iPS-derived hepatocytes would be an unlimited source for materials that are 
genetically homogeneous for conducting consistent pharmaco-toxicological evaluations. For 
example, an iPS-derived hepatocyte library could be established based upon single-nucleotide 
polymorphisms (SNPs) in drug metabolizing enzymes (eg. cytochrome P450s), and this could 
enable evaluation of drug metabolism with specific SNP-type hepatocytes. These data could be 
utilized to design personalized therapies for future “made-to-order” medicine (Medine et al 
2010). 
In this chapter, we describe the developmental progression from a pluripotent stem cell 
state to hepatocytes and provide an overview of protocols for hepatic differentiation of 
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pluripotent stem cells. Enrichment strategies of functional hepatocytes and functional 
evaluation methodologies are also discussed.  
2. Lessons from liver development 
A reasonable approach to induce hepatic differentiation from pluripotent stem cells is to 
recapitulate actual embryonic developmental events in vitro. Liver development occurs 
through a series of cell-to-cell interactions between the embryonic endoderm and its nearby 
mesoderm (Duncan 2003, Zaret 1996). A number of genes and signaling pathways that are 
involved in this process have been identified (Lemaigre & Zaret 2004). Understanding the 
molecular pathways controlling hepatogenesis is essential in designing protocols for 
inducing hepatic differentiation in vitro. Although our knowledge of embryonic liver 
development is based on studies from non-human embryos, it is anticipated that the 
fundamental processes are similar if not identical to those in human liver development. 
Studies from mouse, chicken, zebrafish and Xenopus have shown that much of 
hepatogenesis is evolutionarily conserved (Roberts 2000, Tian & Meng 2006). Numerous 
signals are required at each step of hepatogenic development (Lemaigre & Zaret 2004, Zhao 
& Duncan 2005). Here, we review these sequential events – we have divided them into four 
stages to highlight the crucial cues at each stage for a better understanding of hepatic 
differentiation protocols that will be described in subsequent sections.  
2.1 Stage 1. Toward definitive endoderm 
The earliest event of organogenesis during mouse embryonic development is gastrulation. At 
this phase (ED6.5-7.5), the definitive endoderm layer is formed from mesendoderm lineage 
cells (Tada et al 2005). The process begins with the migration of Brachyury (T) positive cells 
through the anterior region of the primitive streak and through the Node, located at the 
anterior-most position of the streak (Vincent et al 2003). It has been shown that signaling by a 
member of the transforming growth factor (TGF)-β superfamily, specifically Nodal, initiates 
both endoderm and mesoderm formation (Vincent et al 2003). The epidermal growth factor 
family molecule, Cripto-1/FRL1/cryptic, plays a central role as a co-receptor for Nodal. 
Nodal/ALK signaling in conjunction with Cripto contributes to generate endoderm precursor 
cells and for the subsequent specification of definitive endoderm (DE) (Strizzi et al 2005). The 
duration and magnitude of Nodal signaling influence the specification of mesoderm or 
endoderm. The physical position of cells relative to the Node also seems to control this 
specification. Exposure to longer and higher levels of Nodal signaling induce endoderm 
specification, whereas lower stimulation of Nodal signaling promotes differentiation into the 
mesoderm (Schier 2003). Nodal signaling targets a core group of endoderm transcription 
factors genes expression including Sox17, Foxa2 (HNF3) (Shen 2007). 
2.2 Stage 2. Influence from cardiogenic mesodermal cells and septum transversum 
mesenchyme 
Following gastrulation, the definitive endoderm is patterned along the A-P axis into foregut, 
midgut and hindgut progenitor domains (Dessimoz et al 2006). Morphogenesis forms 
foregut and hindgut pockets as the endodermal cup is transformed into a gut tube. At ED8 
the definitive endoderm cells occupy a portion of the ventral foregut adjacent to the heart. 
Signaling cues from cardiogenic mesodermal cells such as fibroblast growth factors (FGFs) 
(Jung et al 1999) and cues from the septum transversum mesenchyme (STM), such as bone 
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morphogenic proteins 2 and 4 (BMP2, BMP4) are essential to direct cell fate to a hepatic 
lineage (Rossi et al 2001). It has been demonstrated that mouse embryonic foregut explants 
express albumin when co-cultured with cardiac mesoderm (Calmont et al 2006, Rossi et al 
2001). Studies using explant systems have shown that the cardiac mesoderm can be replaced 
by exogenous FGF1 or FGF2 supplementation (Jung et al 1999). BMP signaling is required, 
but not sufficient, for hepatic induction in explants (Rossi et al 2001).  
2.3 Stage 3. Hepatoblast proliferation  
The domain that eventually becomes the liver moves to the midgut, and the liver 
diverticulum forms by ED9 (Rifkind et al 1969). By ED9.5, the basal lamina breaks down and 
hepatoblasts delaminate and migrate into the STM. The liver diverticulum expands into a 
pronounced liver bud by ED10. The liver bud then undergoes tremendous growth and 
becomes the major site of fetal hematopoiesis. The massive proliferation and protection from 
apoptosis are regulated by paracrine signals from adjacent mesenchyme. These signals are 
including the FGFs, BMPs, Wnts, and the TGFβ signaling pathways. Hepatocyte Growth 
Factor (HGF) signaling is also required for hepatoblast migration and proliferation 
(Birchmeier et al 2003). 
Although Wnt/-catenin signaling appears to repress liver fate during earlier endoderm 
patterning stages of development, -catenin has the opposite effect and promotes hepatic 
growth in the liver bud at this stage (ED10) (McLin et al 2007, Micsenyi et al 2004, Monga et 
al 2003). Immunohistochemical studies showed TGF-3 expression in the liver bud 
mesenchyme at ED13.5 (Pelton et al 1991). Similarly, Stenvers et al showed a predominant 
expression of the TGF- receptor III (TbetaRIII) mRNA in liver at midgestation. They also 
demonstrated that TbetaRIII gene disruption induced apoptosis in the liver at ED13.5 
(Stenvers et al 2003).  
2.4 Stage 4. A bifurcation point to hepatocyte or cholangiocyte 
The differentiation of bi-potential hepatoblasts into hepatocytes or cholangiocytes begins 
around ED13 of mouse development. Hepatoblasts, adjacent to the portal vein, transform 
into cuboidal cells, which eventually forms the intrahepatic bile ducts during the prenatal 
period through the ductal plate remodeling process (Lemaigre 2003, Raynaud et al 2011), 
while other hepatoblasts gradually differentiate into mature hepatocytes. It has been shown 
that oncostatin M (OSM) promotes hepatic maturation (Kamiya et al 2001) During this 
phase, the liver bud transitions from a hematopoietic organ to a metabolic organ. Coexisting 
hematopoietic cells also play a significant role in the hepatic maturation process. For 
example, OSM is released from the hematopoietic cells and activates a JAK/Stat3 signaling 
pathway via the gp130 receptor (Ito et al 2000, Kamiya et al 1999), and intrahepatic 
structures are organized by ED15. The final maturation of the liver is a gradual process and 
continues into the postnatal period. Many hepatic enzymes such as cytochrome P450s shift 
from a fetal form to a mature form during the postnatal period. 
3. Hepatic differentiation of pluripotent stem cells 
Currently hepatic differentiation strategies from pluripotent stem cells can be classified into 
three approaches; 1) via formation of spontaneous embryoid body (EB), 2) co-culture with 
supporter cells, and 3) directed hepatic differentiation via stepwise stimulation by defined 
growth factors.  
www.intechopen.com
Hepatic Differentiation of Human Embryonic 
and Induced Pluripotent Stem Cells for Regenerative Medicine  
 
307 
3.1 Embryoid body formation and spontaneous hepatic differentiation 
Mouse ESCs aggregate in suspension to form spheroid clumps of cells called embryoid 
bodies (EBs). Removal of leukemia inhibitory factor (LIF) induces spontaneous 
differentiation into three germ layers (Itskovitz-Eldor et al 2000). Chinzei et al reported that 
AFP and albumin gene expressions were detected in EBs after 9 days and 12 days, 
respectively, without additional exogenous growth factors (Chinzei et al 2002). However, 
the spontaneous differentiation of hepatocytes in EBs is inefficient (usually under 10%) and 
is highly cell line dependent (Lavon & Benvenisty 2005, Schwartz et al 2005, Shirahashi et al 
2004). To increase the ratio of hepatic cells in the EBs, differentiation can be directed by 
exposure to exogenous growth factors. Hamazaki and colleagues demonstrated that the 
combination and consecutive supplementation of FGF, HGF, OSM, and dexamethasone 
efficiently induced hepatic differentiation (Hamazaki et al 2001). In regards to human ESCs, 
hepatic induction using the EB formation approach was reported by Schuldiner and 
colleagues (Schuldiner et al 2000). These studies with EB formation provided evidence that 
mouse and human pluripotent stem cells were able to differentiate to the hepatic lineage in 
vitro. The 3D structure of EBs has an advantage over the 2D culture system in further 
inducing functional maturation. However, the uncontrolled heterogeneous cell populations 
in EBs and the variation in size and morphology prohibit further clinical applications. 
3.2 Co-culture of pluripotent stem cells with supporter cells 
Another approach for hepatic differentiation is providing in vivo-like supplements including 
cytokines, growth factors, and extracellular matrixes. These elements can be provided by co-
culturing appropriate supporter cells, such as hepatic mesenchymal cells. A co-culture strategy 
for hepatic differentiation was first applied using Thy1-positive mesenchymal cells derived 
from mouse fetal liver (Ishii et al 2005). An enhanced green fluorescent protein (EGFP)-AFP 
labeling system was used to isolate hepatic lineage committed ES-derived cells, which were 
subsequently co-cultured with the Thy1 positive mesenchymal cells. Several late-phase hepatic 
markers such as tyrosine amino transferase, tryptophan 2,3-dioxygenase, and glucose-6-
phosphatase were expressed in the co-cultured ES-derived hepatocytes. Fair et al reported that 
co-cultured mESCs with chick embryonic cardiac mesoderm cells expressed mesendoderm 
genes, Sox17, HNF3, GATA4, after 24 hours (Fair et al 2003). They also demonstrated that 
the xenogeneic cell-to-cell contact between mESCs and the chick cells, apart from providing 
cytokines/growth factors, may also provide signals via direct cell-to-cell interaction. In 
contrast, Saito et al demonstrated that diffusible factors from mouse fetal liver-derived cells 
were sufficient to stimulate hepatic differentiation of cynomolgus monkey ES cells (Saito et al 
2006). They also demonstrated that induction of hepatic differentiation utilizing the co-culture 
system was faster than chemical/growth factor induction. Soto-Gutierrez et al combined a co-
culture system of human liver nonparenchymal cell lines with growth factors. This protocol 
resulted in the successful derivation of 70% albumin positive cells from mESCs (Soto-Gutierrez 
et al 2007). These data indicate the feasibility of the co-culture system for inducing hepatic 
differentiation from pluripotent stem cells. However, it might be difficult to reproduce hepatic 
differentiation by co-culturing with primary cells as the quality and the secreted factors are 
uncertain. Moreover, the contamination of the supporter cells and the difficulty in the scale-up 
of hepatocyte production are issues that hamper clinical applications. 
3.3 Guided hepatic differentiation with specific factors 
The in vitro developmental capability of ES cells has been shown with spontaneous 
differentiation with EB formation. The co-culture studies indicate that exogenous signals 
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could induce hepatic differentiation. As described in section 2, extensive developmental 
biology studies have uncovered the pathways controlling hepatogenesis. To mimic the 
sequential stimulation of in vivo hepatogenesis, various combinations of stepwise growth 
factor stimulation strategies have been tested.  
The critical first step is to efficiently induce definitive endoderm (DE) commitment of ESCs. 
Based on researches of mesendoderm and definitive endoderm differentiation in rodent and 
Xenopus, it was reasonable to expect that a high concentration of Nodal is key to the 
induction of definitive endoderm differentiation (Schier 2003). In most studies, a high dose 
of Activin A was used as a substitute for Nodal. Activin shares the same receptors (ActRII 
and ALK4) with Nodal but does not require the association of Cripto to initiate the 
Nodal/Smad2 signaling pathway (Strizzi et al 2005). After a few days of Activin treatment, 
most of the ES cells express definitive endoderm genes (Sox17 and Foxa2), while mesoderm, 
pluripotency and the extraembryonic endoderm genes are down regulated (D'Amour et al 
2005, Kubo et al 2004). Further studies indicate that generation of hESC-DE requires two 
conditions: signaling by Activin/Nodal family members and the release from inhibitory 
signals generated by PI3K through insulin/IGF (McLean et al 2007). In this approach, using 
a high-density monolayer culture, pluripotent stem cells are cultured in a feeder cell-free 
system and mesendoderm differentiation is induced by a defined serum-free medium, 
supplemented with high-dose of Activin A (e.g. 100ng/ml) (Yoshie et al 2010).  
The signaling pathways regulating foregut formation can be recapitulated in cell culture by 
the addition of specific growth factors such as FGFs and BMPs. A number of groups have 
used this combination to generate hepatic cells (Dan & Yeoh 2008, Ochiya et al 2009). The 
endoderm specification stage is followed by HGF stimulation to expand the hepatoblast 
population (LaBrecque 1994). Hepatic maturation is normally regulated and promoted by 
some combination of OSM and Dexamethasone. (Agarwal et al 2008, Baharvand et al 2008, 
Cai et al 2007, Soto-Gutierrez et al 2006b, Teratani et al 2005).  
Hay and colleagues introduced a similar stepwise induction concept, except using chemicals 
to induce hepatic differentiation in ES and iPS cells (Hay et al 2008a, Hay et al 2008b, 
Sullivan et al 2010). A combination of Activin A and the histone deacetylase inhibitors 
(HDI), sodium butyrate, were utilized for the definitive endoderm induction and 1% DMSO 
for further hepatic specification (Hay et al 2008b). Although the effect of butyrate for 
inducing differentiation has been known for a long time (Leder & Leder 1975), the role of 
HDI in the hepatic differentiation process was not totally elucidated. McLean showed that a 
combination of Activin and a PI3K inhibitor is more efficient to induce DE differentiation 
(McLean et al 2007). Recent progress on studies in signal transduction pathways has led 
researchers to control not only the initiation of signal transduction by adding exogenous 
growth factors, but also the regulation of intracellular signaling to induce hepatic 
differentiation in a more precise and efficient manner. Touboul et al used the PI3K inhibitor, 
LY294002, for DE induction and activin receptor-like kinase (ALK) 5 inhibitor, SB431542, for 
hepatic specification. Currently, these protocols still require combinations with recombinant 
growth factors. Since mass production of these recombinant proteins are cost prohibitive, a 
totally defined chemical protocol would be ideal for a large-scale hepatocyte production.  
Although hepatic differentiation protocols are now more sophisticated, fully differentiated 
stem cell-derived hepatocytes that possess identical hepatic functions to primary adult 
hepatocytes have yet to be produced. Using a unique primary hepatocyte culture system, 
Michalopoulos's group demonstrated that a combination of dexamethasone, HGF, and EGF 
was required for formation of liver-like tissue. Dexamethasone induces expression of both 
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HNF4 and C/EBP-, essential transcription factors for hepatocyte differentiation, while 
HGF and EGF induce members of the TGF- family and HNF6, which are essential for 
maintenance of hepatic functions (Michalopoulos et al 2003). Although this unique culture 
system has not been tested with stem cell-derived hepatic cells, this combination and culture 
system may be essential to achieve further hepatic maturation.  
4. Enrichment strategies of stem cell derived hepatocytes 
Despite utilizing these well-designed differentiation protocols on mouse and human ES 
cells, hepatic induction from pluripotent stem cells results in mixtures with non-hepatic 
cells. Generally speaking, in the areas of stem cell-derived cell studies, there has not been a 
differentiation protocol that is able to induce 100% of this desired target cells based upon 
current technologies. This is one of the issues that is hindering further clinical development. 
Particularly in the use of pluripotent stem cells, contamination with undifferentiated cells is 
one of the biggest concerns due to their tumorigenic potential (Ben-David & Benvenisty 
2011, Dressel et al 2008). Therefore, further investigations will be necessary to obtain 
clinically applicable stem cell-derived hepatocytes. One of the approaches is to develop 
techniques that allow for isolation and purification of specific hepatic subtypes.  
For basic research, it is common to use genetic selection techniques. Under this strategy, 
undifferentiated pluripotent stem cells are genetically modified to carry either a reporter 
gene, usually a green fluorescence protein (EGFP) gene or an antibiotic resistance gene 
under the transcriptional control of a hepatic-promoter such as alpha-fetoprotein (Yin et al 
2002). The transgenic cells are then induced to differentiate and subsequently selected based 
on the activation of the hepatocyte-specific promoter. The major disadvantage of this 
approach is the risks associated with the genetic modification which may lead to insertional 
oncogenesis. In addition, these transcriptional markers are also common to immature 
hepatocytes. It is, therefore difficult to designate one gene as a definitive single marker of 
hepatic differentiation.  
An endogenously expressed surface marker, asialoglycoprotein receptor (ASGPR), has been 
proposed as a cell surface marker for functional hepatocytes (Li et al 2008, Treichel et al 
1995). Recent studies have utilized ASGPR to identify mature hepatic cells from a mixed 
population of fetal hepatocytes (Ring et al 2010). ASGPR is a transmembrane hepatocellular 
surface carbohydrate binding glycoprotein that lacks terminal sialic acid residues 
(=asialoglycoproteins). Characterization of the ASGPR has revealed its functional role in the 
binding, internalization and transport of a wide range of glycoproteins in a selective manner 
via the process of receptor-mediated endocytosis. The expression of the ASGPR has been 
clinically correlated to loss of hepatic functions in liver diseases associated with cancer, viral 
hepatitis, and cirrhosis. Basma et al enriched hESC-derived hepatic cells using the ASGPR 
marker (Basma et al 2009). Although the G6Pase, albumin, and TAT mRNA expressions 
were dramatically improved by this enrichment step, mRNA expression of both Oct4 and 
AFP were still detectable. This data indicates that a single enrichment step could not 
completely eliminate the undifferentiated stem cell or the progenitor cell contamination. 
Kumashiro et al used a silica-based colloidal medium (Percoll) and PECAM-1 antibodies to 
separate mESCs-derived hepatocytes from Oct4 positive undifferentiated cells. The ES-
derived hepatocytes were transplanted into the CCl4-injured mouse liver and this led to 
improved liver function. Importantly, unlike unselected ES-derived hepatocytes, the 
enriched ES-derived hepatocytes did not develop teratomas in the recipients’ liver 
(Kumashiro et al 2005).  
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Conclusively, the hepatic enrichment studies demonstrate the advantages of selecting 
hepatic cells from mixed ES-derived cell population. However, there is to date, no single 
standard technology to achieve sufficient hepatocyte enrichment or non-hepatic cell 
exclusion. The influence of other cell types on hepatic differentiation is one aspect that 
requires further studies. Non-hepatic cells such as cholangiocyte contamination may have a 
positive influence for further maturation in stem cell-derived hepatic cells. For future 
clinical applications, genetic modification of stem cell will not be acceptable. Although the 
ASGPR enrichment protocol is promising, the need for a large quantity of antibody remains 
a substantial financial burden for large-scale production of stem cell-derived hepatocytes. 
Thus, additional investigations are needed to find novel strategies to enrich clinically viable 
stem cell-derived hepatocytes.  
5. Characteristics of pluripotent stem cell derived hepatocytes 
One of the difficulties for stem cell research is the interpretation of in vitro data on the extent 
of terminal differentiation. Since human primary hepatocytes lose their hepatic functions in 
vitro within a week after their isolation, it is clearly a challenge to induce full maturation 
status equivalent to that of adult hepatocytes in stem cell-derived hepatocytes in vitro. With 
this in mind, the in vitro evaluation for hepatic differentiation has to be undertaken very 
carefully using multi-pronged approaches. The evaluation should be conducted at 1) the 
transcription level, 2) the translation level, 3) performing biochemical (in vitro) functional 
tests, as well as 4) in vivo functional assays. 
5.1 Transcriptional evaluation. Hepatic marker genes expression 
Many genes have been proposed as hepatocyte-specific genes. The most commonly cited 
genes are; albumin, alpha-fetoprotein (AFP), cytokeratin-18, glucose-6-phosphatase (G6P), 
phosphoenolpyruvate carboxykinase (PEPCK), alpha-1-antitrypsin (A1AT), bilirubin, 
uridine diphosphate-glucuronosyltransferase, coagulation factor VII. However, some of 
these are also expressed in other tissues such as extra-embryonic yolk sac. AFP, for example, 
is expressed in both the liver and the yolk sac. Therefore, AFP expression needs to be 
demonstrated along with definitive endoderm marker genes, Sox17 and CXCR4. 
Transcriptome studies on mouse liver development have revealed that the expression 
patterns of these hepatic markers are dramatically altered during hepatogenesis. For 
instance, Jochheim et al. demonstrated that HNF4 gene expression peaked on ED11.5 and 
decreased until ED13.5, after which, it gradually increased but its levels were not as high as 
at ED11.5 (Jochheim et al 2003). Therefore, quantitative RT-PCR data must be carefully 
interpreted, as a downregulation of HNF4 mRNA expression could still be an indication of 
increased hepatocyte maturation. Genes encoding cytochrome P-450 (CYP)-7A1, bilirubin, 
uridine diphosphate-glucuronosyltransferase, coagulation factor VII, and asialoglycoprotein 
receptors are considered late phase hepatic marker genes and are not expressed in the yolk 
sac. Therefore, these genes could be useful as markers for mature hepatocytes. In contrast, 
G6P, CYP3A4 and PEPCK are also deemed late-phase marker genes, however, their 
expression is not liver specific. CYP7A1 is a member of the cytochrome P450 superfamily of 
enzymes. This liver specific endoplasmic reticulum membrane protein is involved in the 
cholesterol catabolic pathway, which converts cholesterol to bile acids. Other CYP enzymes 
are responsible for oxidative metabolism of most therapeutic drugs. Therefore, it is 
important to demonstrate the expression of these genes in the stem cell-derived hepatic cells 
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for drug testing. Among the CYP enzymes, 3A4, 1A2, 2C19, 2D6, are dominant players for 
drug metabolism in human liver. 
Ideally the gene expression levels in stem cell-derived hepatic cell at the end of the 
differentiation protocol should be comparable to that of an adult hepatocyte. Concurrently, 
evaluations for non-hepatocyte specific genes to determine the extent of differentiation to 
specific hepatic lineage should also be performed.  
With regards to the development of drug metabolizing enzymes such as CYP genes, both 
the pattern and the level of expressions are important. Many metabolic and detoxifying 
enzymes are expressed at significant levels only after birth. Therefore, the gene expression 
ratio of the fetal form to the adult form could be used as a determinant of the status of 
hepatic maturation. For example, fetal liver cells express CYP3A7, a fetal form of CYP3A4. 
Higher 3A4/3A7 ratio indicates increased hepatic maturation of stem cell-derived hepatic 
cells (Ek et al 2007, Miki et al 2011).  
5.2 Translational evaluation. Hepatic marker proteins expression 
Gene expression does not necessarily translate to protein production and activity. Using a 
hepatic differentiation protocol, Hay et al demonstrated that Oct4 protein was undetectable 
after the second day, while Oct4 mRNA remains detectable until day 11 of the protocol. 
Along the same vein, albumin mRNA expression was observed at day 11 but albumin 
protein was detected only starting at day 15 (Hay et al 2008b). Therefore, 
immunohistochemistry and/or Western blot analyses must be performed to verify the 
expression of key proteins at the end of any differentiation protocol. AFP, Albumin, A1AT, 
and cytokeratins (8, 18, 19) are common proteins that were used in many reports. As 
mentioned in section 4, some cell surface marker proteins (e.g. ASGPR) are also important. 
5.3 Biochemical functional assay 
Demonstration of albumin production and secretion from stem cell-derived hepatic cells is 
the gold standard assay to demonstrate functional protein synthesis. In the human body, 
albumin is the most abundant protein in serum and is produced specifically by the liver. 
Therefore, serum albumin has been used as an indicator to evaluate liver function in a 
clinical setting. Although albumin production and secretion are essential, it is however 
insufficient to use this as a marker for stem cell-derived hepatic cells. It has been shown the 
albumin gene is expressed at a relatively early stage of hepatogenesis, and furthermore, 
visceral endoderm cells such as yolk sac cells also produce albumin (Meehan et al 1984). 
Therefore, albumin production from stem cell-derived hepatic cells must be further 
supported through a combination of other assays.  
The ability to metabolize ammonia is also a standard assay to evaluate hepatic detoxification 
function. In vivo, ammonia is a metabolic product generated from dietary amino acids, and 
80-90% of ammonia is converted into urea by hepatocytes through the urea cycle. To test 
this function in vitro, excess amount of ammonium chloride is added to the culture medium 
(ammonia challenge). Ammonia clearance or urea production can then be measured as 
functional readout of the assay. Since precise parameter adjustment for measuring ammonia 
level in culture media is difficult, the standard protocol is measuring urea concentration in 
the supernatant via the enzymatic urease method. A pitfall in this assay is the possibility of 
arginase leakage from damaged cells due to the excess ammonium chloride, which could 
produce urea independently from the urea cycle activity. Therefore, the acquisition of urea 
metabolism function should be further confirmed by the expression of key enzymes in the 
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urea cycle, such as arginase I (ARG1), argininosuccinate lyase (ASL), argininosuccinate 
synthetase 1 (ASS1), carbamoyl-phosphate synthetase 1 (CPS1), and ornithine 
carbamoyltransferase (OTC) (Mavri-Damelin et al 2008, Miki et al 2011). 
To meet the demand for pharmaco-toxicological applications, demonstration of activities of 
xenobiotic-metabolizing phase I and phase II enzymes and phase III transporters must be 
satisfied (Xu et al 2005). To evaluate phase I activities, CYP-dependent monooxygenase 
activity assays; 7-ethoxycoumarin-O-deethylase (ECOD assay) (Lubet et al 1985), 7-
ethoxyresorufin-O-deethylase (EROD assay), and specific oxidation of testosterone are 
commonly used. In measuring phase II activities, glucuronosyltransferase activity and 
sulfotransferase activity toward p-nitrophenol, and glutathione S-transferase activity are 
commonly used. Functional assays for phase III transporters have yet to be standardized. 
Measurement of fluorescent protein conjugated bile acid could be useful to evaluate one of 
the phase III transporters, i.e. the bile salt export pump (BSEP/ABCB11), for activity in stem 
cell-derived hepatocytes (Yamaguchi et al 2010).  
5.4 In vivo analysis 
These in vitro hepatic functional assays are essential and useful. However, the most 
definitive proof for the functionality of stem cell-derived hepatic cells would be the 
demonstration of hepatic engraftment in vivo using animal models (Soto-Gutierrez et al 
2006a, Yamamoto et al 2003). It would be ideal if stem cell-derived hepatic cells could 
improve survival rates in lethal disease models. Transgenic mouse models of congenital 
liver diseases would be candidates for such assays. The fumarylacetoacetate hydrolase 
(FAH) deficiency mouse model (Lagasse et al 2000) and urokinase-type plasminogen 
activator-transgenic SCID mice (Tateno et al 2004) have been previously and provide a 
means to test stem cell-derived hepatocytes in a liver transplantation setting. Unfortunately 
such animal models are not widely available and also require significant technical expertise 
to perform hepatocyte transplantation in neonatal animals. 
Nevertheless, whether human or rodent, primary hepatocytes tend to lose their 
differentiated characteristics in culture. One question that arises is whether the stem cell-
derived hepatic cells have to be fully differentiated in vitro. It is anticipated that stem cell-
derived hepatic progenitor cells spontaneously differentiate to fully mature hepatocytes in 
their correct endogenous environment. Once hepatic lineage commitment is confirmed, stem 
cell-derived hepatic progenitor cells could be an acceptable source for cell replacement 
therapy. The endogenous mouse liver environment is suitable to test this hypothesis. It is 
therefore extremely important to establish standard animal models that are easy to 
experiment with, and also widely available for stem cell-derived hepatic cell 
transplantation.  
6. Conclusion and future perspectives 
Hepatic differentiation is a sequential dynamic event that involves various types of cells and 
complex signaling networks. Although the signaling pathways and growth factors that are 
involved in definitive endoderm specification have been well documented, only portions of 
the mechanisms involved in the human hepatogenic development have been defined. 
Therefore, the goal of inducing directed differentiation of pluripotent stem cells toward 
hepatocytes remains a big challenge. A number of differentiation protocols have been 
described to generate hepatocytes from pluripotent stem cells. Collectively, various hepatic 
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differentiation studies demonstrate how the exposure of various growth factors to 
pluripotent stem cells, with the appropriate timing and doses, is essential for directing the 
differentiation process from early mesendoderm via definitive endoderm towards more 
functionally mature hepatocytes. Based on the recent advances in the field of developmental 
biology, hepatic differentiation protocols have been modified to provide more than 70% 
albumin positive cells from mESCs (Soto-Gutierrez et al 2007) and 35% of ASGPR positive 
cells from hESCs (Touboul et al 2010). It appears that iPS cells possess a similar capacity to 
hES cells to generate hepatocytes using similar differentiation protocols (Sullivan et al 2010).  
It must be noted that the stem cell-derived hepatocytes described to date generally exhibit 
fetal hepatocyte-like gene expression profiles and immature functional characteristics 
compared to authentic adult primary hepatocytes. Recent finding suggested that a 3D 
dynamic bioreactor culture system which provides an in vivo-like culture environment 
induced teratoma-like multi-directional differentiation of human ESCs (Gerlach et al 2010). 
When a hepatic differentiation protocol was applied in this system, the 3D dynamic culture 
system induced further hepatic maturation, including tissue-like structure formation (Miki 
et al 2011). Although the superiority of the culture conditions in the 3D dynamic culture 
system has been clearly demonstrated, it is difficult to determine which parameters are 
critical for this advantage in hepatic maturation. Using matrigel or collagen gel, it has been 
shown that static 3D culture conditions prolong hepatic function of primary hepatocytes 
(Kono et al 1997). It has been proposed that the 3D structure allows more physiological cell-
to-cell interactions, and induces polarity in hepatocytes (Haouzi et al 2005). Baharvand et al 
demonstrated that hESCs are more efficiently differentiated to hepatic cells under static 3D 
culture conditions than conventional 2D culture conditions (Baharvand et al 2008).  
Dynamic culture conditions are, not surprisingly, more advantageous than static culture 
conditions (Vinci et al 2011). Unlike static cultures, the dynamic culture system provides 
continuous and gradual medium change under controlled oxygen tension and temperature. 
Taken together, the dynamic 3D culture system can provide a more physiological and 
homeostatic environment that could be favorable for stem cell-derived hepatocyte 
maturation. The continuous supply of fresh medium via nano-size porous hollow fibers also 
provides micro steady flow around the cells (Gerlach et al 2010) and low shear stress that 
could further stimulate maturation signals through sensory systems (e.g. cilia) on the 
polarized hepatic cells (Decaens et al 2008). Furthermore, it is noteworthy that in the human 
body, the liver passively but dynamically moves with the movements of diaphragm. In 
addition to the oxygen concentration in the blood flow, such movement could be a factor to 
induce rapid postnatal hepatic maturation events such as cytochrome isotype switching 
from CYP3A7 to 3A4.  
As reviewed, the current differentiation protocols demonstrated the feasibility of hepatic cell 
production from pluripotent stem cells. Further optimization will be required to better 
define hepatic differentiation protocols and improved culture conditions to obtain fully 
differentiated functional hepatocytes in vitro. On the other hand, for cell replacement 
therapy applications, such in vitro full maturation may not be essential. Both fetal and adult 
hepatocytes demonstrated bilirubin conjugating activity in the Gunn rat after cell 
transplantation (Borel-Rinkes et al 1992). Hepatic progenitor cells could mature in the 
endogenous hepatic environment and thereby provide therapeutic effects to patients. The 
direction of research for this goal will be generating hepatic lineage committed cells in vitro, 
establishing an appropriate enrichment protocol, and critically evaluating the efficacy and 
safety of these cells in animal models.  
www.intechopen.com
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
314 
In conclusion, the promise of pluripotent stem cells for the generation of hepatocytes and 
with further investigations will eventually lead us to a more in-depth understanding of 
mechanisms of hepatogenesis and hepatic maturation. The widespread utility of pluripotent 
stem cell-derived functional hepatocytes for basic research and pharmaceutical applications, 
could also become a reality. In the future, stem cell-derived hepatocytes are anticipated to 
have an enormous impact on the treatment of liver disease. 
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differentiation. This book provides a snapshot of current research on the differentiation of embryonic stem cells
to a wide variety of cell types, including neural, cardiac, endothelial, osteogenic, and hepatic cells. In addition,
induced pluripotent stem cells and other pluripotent stem cell sources are described. The book will serve as a
valuable resource for engineers, scientists, and clinicians as well as students in a wide range of disciplines.
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